Mirum Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Mirum Pharmaceuticals's earnings have been declining at an average annual rate of -12.9%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 73.5% per year.
Key information
-12.9%
Earnings growth rate
13.6%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | 73.5% |
| Return on equity | -43.0% |
| Net Margin | -32.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Mirum Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 307 | -100 | 192 | 128 |
| 30 Jun 24 | 264 | -109 | 178 | 122 |
| 31 Mar 24 | 224 | -159 | 161 | 111 |
| 31 Dec 23 | 186 | -163 | 146 | 103 |
| 30 Sep 23 | 145 | -164 | 126 | 103 |
| 30 Jun 23 | 116 | -176 | 112 | 103 |
| 31 Mar 23 | 96 | -129 | 100 | 106 |
| 31 Dec 22 | 77 | -136 | 89 | 107 |
| 30 Sep 22 | 52 | -42 | 82 | 104 |
| 30 Jun 22 | 39 | -53 | 76 | 108 |
| 31 Mar 22 | 32 | -70 | 69 | 117 |
| 31 Dec 21 | 19 | -84 | 59 | 131 |
| 30 Sep 21 | 16 | -179 | 47 | 133 |
| 30 Jun 21 | 11 | -153 | 36 | 119 |
| 31 Mar 21 | 0 | -132 | 27 | 102 |
| 31 Dec 20 | 0 | -103 | 23 | 82 |
| 30 Sep 20 | 0 | -84 | 20 | 66 |
| 30 Jun 20 | 0 | -78 | 18 | 62 |
| 31 Mar 20 | 0 | -68 | 15 | 55 |
| 31 Dec 19 | 0 | -53 | 12 | 43 |
| 30 Sep 19 | 0 | -61 | 8 | 32 |
Quality Earnings: MIRM * is currently unprofitable.
Growing Profit Margin: MIRM * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MIRM * is unprofitable, and losses have increased over the past 5 years at a rate of 12.9% per year.
Accelerating Growth: Unable to compare MIRM *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MIRM * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.7%).
Return on Equity
High ROE: MIRM * has a negative Return on Equity (-43.02%), as it is currently unprofitable.